

Isocitrate Dehydrogenase Kinase/Phosphatase: Identification of Mutations Which Selectively Inhibit Phosphatase Activity

TIMOTHY P. IKEDA,† ELIZABETH HOUTZ, AND DAVID C. LAPORTE*

Department of Biochemistry, University of Minnesota, Minneapolis, Minnesota 55455-0347

Received 16 September 1991/Accepted 12 December 1991

Mutations in *aceK*, the gene encoding isocitrate dehydrogenase kinase/phosphatase, which selectively inhibit phosphatase activity have been isolated. These mutations yield amino acid substitutions within a 113-residue region of this 578-residue protein. These mutations may define a regulatory domain of this protein.

In *Escherichia coli*, the Krebs cycle enzyme isocitrate dehydrogenase (IDH) is regulated by reversible phosphorylation (1, 3). The phosphorylation of IDH controls the partitioning of isocitrate between the Krebs cycle and the glyoxylate bypass. The flow of isocitrate through this bypass is essential for growth on acetate, since it avoids the quantitative loss of the acetate carbons as CO₂ in the Krebs cycle (6, 7). During growth on acetate, ca. 70% of the IDH is maintained in the inactive, phosphorylated form, forcing isocitrate through the glyoxylate bypass (2, 8, 11, 13, 14). In most genetic backgrounds, phosphorylation of IDH appears to be essential for use of the glyoxylate bypass, since mutations which eliminate IDH kinase prevent growth on acetate (13).

The phosphorylation and dephosphorylation of IDH are catalyzed by a bifunctional protein, IDH kinase/phosphatase, expressed from the *aceK* gene (5, 9, 10). The IDH kinase and IDH phosphatase reactions appear to occur at the same active site, a conclusion supported by the observation that a mutation at the consensus ATP binding site eliminates both activities (18).

One of the approaches which we have taken to examine the structure of IDH kinase/phosphatase has been the random mutagenesis of *aceK*, the gene which encodes this protein. Our strategy has been to screen for alleles which have lost the ability to complement a null mutation in *aceK* and then assay the products of these candidate alleles for IDH kinase and IDH phosphatase activities. In a previous report (4), we described the isolation of two alleles of *aceK* (*aceK3* and *aceK4*) whose products retain IDH kinase activity but have suffered drastic reductions in their IDH phosphatase activities. We have subsequently isolated three additional alleles whose products have similar defects (Table 1). Four of these alleles (*aceK3*, *aceK4*, *aceK5*, and *aceK7*) were generated by replication of a plasmid bearing *aceK*⁺ in the mutator strain W3550 (*mutD5*) (15). To increase the range of possible mutations, we have also employed chemical mutagenesis with hydroxylamine (16). This method resulted in the generation of an additional allele whose product has selectively lost IDH phosphatase activity, *aceK6*. In order to ensure that each allele had resulted from a single point mutation, we employed relatively mild conditions for mutagenesis. Replication in strain W3550 yielded 0.3% noncomplementing alleles, while treatment with hy-

droxylamine generated these alleles in only 0.1% of transformants.

The locations of the mutations were approximated by testing the abilities of fragments of *aceK*⁺ to direct repair of these mutations (17). In this procedure, each mapping plasmid (which carries a fragment of *aceK*⁺) was linearized by restriction digestion and then was mixed with a plasmid carrying a mutant allele of *aceK* which had been linearized by digestion at a different site. Circular heteroduplexes were formed between the linearized mutant and mapping plasmids by denaturation and gradual renaturation. The heteroduplex plasmids were selected, since they could transform recipient strains (because they were circular) while the original plasmids could not (because they were linear). The success of the repair process was tested by examining the abilities of the resulting clones to restore strain IL2 (*ΔaceK*) (18) to wild-type growth on acetate medium. All of the mutations fell within the region of *aceK* between nucleotides 1093 and 1492 relative to the start codon (Fig. 1).

Sequence analyses of the regions which had been delineated by the initial mapping procedure identified a single-base substitution in each of the mutant alleles (Table 2). The resulting amino acid substitutions all occur within a 113-amino-acid segment of IDH kinase/phosphatase, a protein which has a total of 578 residues (5).

While our mapping and sequencing results identified only one mutation in each allele, there was a possibility that other mutations remained undetected. To ensure that each of these mutations was uniquely responsible for the selective elimination of IDH phosphatase activity, we recloned restriction fragments containing the mutations into a wild-type allele. In

TABLE 1. Enzymatic activities of IDH kinase/phosphatase derivatives^a

Allele	Enzyme activity (mU/mg) ^b	
	IDH kinase	IDH phosphatase
<i>aceK</i> ⁺	184	125
<i>aceK3</i>	297	0.5
<i>aceK4</i>	110	1.9
<i>aceK5</i>	174	0.0
<i>aceK6</i>	634	0.0
<i>aceK7</i>	507	0.5

^a Restriction fragments containing the indicated mutations were recloned into *aceK*⁺ plasmids to ensure that only a single mutation was present in each allele (see text). Data presented here, which were derived from the reconstructed alleles, were indistinguishable from those obtained with the original isolates.

^b Assayed in sonicated extracts as described previously (10, 11).

* Corresponding author.

† Present address: Department of Plant Pathology, University of California, Berkeley, CA 94720.




FIG. 1. Location of mutations by heteroduplex analysis. (A) The sequences from *aceK*⁺ carried by each mapping plasmid are indicated with open boxes. The shaded area is the region of *aceK*⁺ required for repair of all of the mutant alleles. (B) Results of the attempts to repair the point mutations using the fragments of *aceK*⁺ carried by the mapping plasmids. The percentages of transformants capable of growth on acetate are indicated.

each case, the entire nucleotide sequence of the transferred fragments had been determined. Complementation testing (not shown) and assay for enzymatic activities (Table 1) of the resulting clones demonstrated that the mutations which had been identified were uniquely responsible for the observed effects.

Our working model for IDH kinase/phosphatase proposes that the kinase and phosphatase reactions occur within the same active site and that IDH phosphatase activity results from the kinase back reaction tightly coupled to ATP hydrolysis (for a review, see reference 12). If the IDH kinase and IDH phosphatase reactions occur at the same active site, then it seems unlikely that the mutations which selectively eliminate phosphatase activity are defining a domain of the protein which is unique to IDH phosphatase. Rather, these mutations may define a domain which participates in the regulation of the relative activities of IDH kinase and IDH phosphatase. Consistent with this possibility, the mutations in *aceK3* and *aceK4* have substantially altered the effector sensitivities of the residual IDH phosphatase activities of their products: the activation constants for 3-phosphoglycerate, pyruvate, and AMP have been increased from 10- to

>100-fold, while the relative activation has increased from 5- to >10-fold compared with that of the wild-type protein (4a).

Although the identified mutations may define a regulatory domain, the selective inhibitions of IDH phosphatase activity which they produce result from changes in the structure of the active site. These structural differences may affect any of a variety of kinetic processes, such as competition between the kinase, phosphatase, and ATPase activities of these proteins. While the mutations which we have identified have had similar effects on the kinetic behaviors of IDH kinase/phosphatase, their effects are not identical. For example, the IDH kinase activities of the products of *aceK6* and *aceK7* are much greater than those of the wild-type protein and the other three mutant proteins. Correlation of these structural, regulatory, and catalytic effects should provide considerable insight into the properties of the wild-type protein.

We thank Jane Kauth and Constance Stueland for assistance with some of these experiments and James Howard for a critical reading of the manuscript.

This work was supported by Public Health Service grant GM33927 and Research Career Development award DK01722, both from the National Institutes of Health.

REFERENCES

- Bennett, P. M., and W. H. Holms. 1975. Reversible inactivation of isocitrate dehydrogenase of *Escherichia coli* during growth on acetate. *J. Gen. Microbiol.* **87**:37-51.
- Borthwick, A. C., W. H. Holms, and H. G. Nimmo. 1984. The phosphorylation of *Escherichia coli* isocitrate dehydrogenase in intact cells. *Biochem. J.* **222**:797-804.
- Garnak, M., and H. C. Reeves. 1979. Phosphorylation of isocitrate dehydrogenase of *Escherichia coli*. *Science* **203**:1111-1112.
- Ikeda, T. P., and D. C. LaPorte. 1991. Isocitrate dehydrogenase kinase/phosphatase: alleles of *aceK* that express kinase but not phosphatase activity. *J. Bacteriol.* **173**:1801-1806.
- Ikeda, T., C. Romfo, and D. C. LaPorte. Unpublished data.
- Klump, D. J., D. W. Plank, L. J. Bowdin, C. S. Stueland, T. Chung, and D. C. LaPorte. 1988. Nucleotide sequence of *aceK*, the gene encoding isocitrate dehydrogenase kinase/phosphatase. *J. Bacteriol.* **170**:2763-2769.
- Kornberg, H. L. 1966. The role and control of the glyoxylate cycle in *Escherichia coli*. *Biochem. J.* **99**:1-11.
- Kornberg, H. L., and N. B. Madsen. 1951. Synthesis of C4-dicarboxylic acids from acetate by a "glyoxylate bypass" of the tricarboxylic acid cycle. *Biochim. Biophys. Acta* **24**:651-653.
- Koshland, D. E. J., K. Walsh, and D. C. LaPorte. 1985. Sensitivity of metabolic fluxes to covalent control. *Curr. Top. Cell. Regul.* **27**:13-22.
- LaPorte, D. C., and T. Chung. 1985. A single gene codes for the kinase and phosphatase which regulate isocitrate dehydrogenase. *J. Biol. Chem.* **260**:15291-15297.
- LaPorte, D. C., and D. E. Koshland, Jr. 1982. A protein with kinase and phosphatase activities involved in the regulation of the tricarboxylic acid cycle. *Nature (London)* **300**:458-460.
- LaPorte, D. C., and D. E. Koshland, Jr. 1983. Phosphorylation of isocitrate dehydrogenase as a demonstration of enhanced sensitivity in covalent regulation. *Nature (London)* **305**:286-290.
- LaPorte, D. C., C. S. Stueland, and T. Ikeda. 1989. Isocitrate dehydrogenase kinase/phosphatase. *Biochimie* **71**:1051-1057.
- LaPorte, D. C., P. E. Thorsness, and D. E. Koshland, Jr. 1985. Compensatory phosphorylation of isocitrate dehydrogenase: a mechanism for adaptation to the intracellular environment. *J. Biol. Chem.* **260**:10563-10568.
- LaPorte, D. C., K. Walsh, and D. E. Koshland, Jr. 1984. The branch point effect: ultrasensitivity and subsensitivity to metabolic control. *J. Biol. Chem.* **259**:14068-14075.

TABLE 2. Summary of mutations

Allele	Nucleotide substitution ^a	Amino acid substitution ^b
<i>aceK3</i>	A(1118)G	Q(373)R
<i>aceK4</i>	A(1241)G	Y(414)C
<i>aceK5</i>	G(1414)T	V(472)F
<i>aceK6</i>	G(1429)A	D(477)N
<i>aceK7</i>	C(1093)T	R(365)C

^a The format used is N₁ (position) N₂, where N₁ and N₂ are the wild-type and substituted bases and the number in parentheses indicates the position relative to the first base of the initiation codon.

^b The format used is A₁ (position) A₂, where A₁ and A₂ are the wild-type and substituted amino acid residues and the number in parentheses indicates the position relative to the N-terminal methionine in the primary translation product.

15. **McCoy, J. M., and H. G. Khorana.** 1983. Introduction and characterization of amber mutations in the bacteriorhodopsin gene. *J. Biol. Chem.* **258**:8456–8461.
16. **Schatz, P. J., F. Solomon, and D. Botstein.** 1988. Isolation and characterization of conditional-lethal mutations in the TUB1 alpha-tubulin gene of the yeast *Saccharomyces cerevisiae*. *Genetics* **120**:681–695.
17. **Shortle, D., and B. Linn.** 1985. Genetic analysis of staphylococcal nuclease: identification of three intragenic “global” suppressors of nuclease-minus mutations. *Genetics* **110**:539–555.
18. **Stueland, C. S., T. P. Ikeda, and D. C. LaPorte.** 1989. Mutation of the predicted ATP binding site inactivates both activities of isocitrate dehydrogenase kinase/phosphatase. *J. Biol. Chem.* **264**:13775–13779.